U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07327359) titled 'A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia' on Dec. 04, 2025.
Brief Summary: This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
Study Start Date: Dec. 04, 2025
Study Type: INTERVENTIONAL
Condition:
Androgenetic Alopecia (AGA)
Intervention:
DRUG: OLX72021
Low Dose
DRUG: OLX72021
Mid Dose
DRUG: OLX72021
High Dose
DRUG: Placebo
Placebo
Recruitment Status: RECRUITING
Sponsor: Olix Pharmaceuticals, Inc.
Published by HT Digital Content Services with permis...